Lydus Medical, a Ra’Anana, Israel-based developer of a novel product line for automating the creation of small blood vessel anastomoses, raised $2.7m in Pre-A funding.
The round was led by an undisclosed US based strategic player with the participation from Sanara Ventures, and existing backers Mor Research, Technion and Leon Recanati’s private equity investment company, Glenrock.
The company intends to use the funds to accelerate FDA clearance while scaling product development and prepare for market entry.
Led by Jessica Weiss, CEO, Lydus developed the Vesseal, a surgical device that enables precise, symmetrical and rapid connection of blood and lymph vessels of tiny diameters, ranging from 4.0 to 0.5mm, for complicated procedures, from breast reconstruction and lymphedema to bypass surgery and vascular access for hemodialysis. Lydus pipeline includes a diverse portfolio of products, all based on a patented invention.
The company is a portfolio company of Sanara Ventures – a JV of Teva and Philips and an anastomosis technology provider.
FinSMEs
24/05/2021